Oncocyte named in Top 5 as one of Orange County’s Best Places to Work in 2020 in its first year
IRVINE, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced it has been named as one of the 2020 Best Places to Work in Orange County. Oncocyte placed number 4 out of 40 in the medium-size company category. The awards program was created in 2009 and is a project of the Orange County Business Journal and Best Companies Group.
“Great technologies and great strategies don’t do great things; great people accomplish great things,” commented Ron Andrews, CEO of Oncocyte. “While our world of molecular diagnostics can be extremely technically oriented, having the right employees who can combine scientific brilliance with a heart for the patients we serve is essential to our success. We are blessed to have an incredibly talented, mission-oriented team who show up each day with humility and genuine care for one another. This combination is a foundational organizational attribute given the pace at which we expect everyone to work. We are very honored to be ranked in this year’s list given how young we are as a company here in Orange County, and owe a big ‘thank you’ to our dedicated employees!”
This county-wide survey and awards program was designed to identify, recognize, and honor the best employment places in Orange County, California, benefiting the county's economy, workforce, and businesses.
To be considered for participation, employers had to fulfill the following eligibility requirements:
- Have at least 15 employees working in Orange County;
- Be a for-profit or not-for-profit business or government entity;
- Be a publicly or privately held business;
- Have a facility in Orange County; and
- Must be in business a minimum of 1 year.
Organizations from across the county entered the two-part process to determine the Best Places to Work in Orange County. First, an evaluation of the employer's workplace policies, practices, and demographics worth approximately 25% of the total evaluation. Second, an employee survey to measure the employee experience worth approximately 75% of the full assessment. The combined scores determined the top organizations and the final ranking. Best Companies Group managed the overall registration and survey process in Orange County, analyzed the data, and used their expertise to determine the final ranking.
For more information on the survey process for the Best Places to Work in Orange County program, visit www.BestPlacestoWorkOC.com or contact Jackie Miller at 877-455-2159.
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company’s proprietary tests and pharmaceutical company services aim to save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while driving the growth of its revenue. Oncocyte recently launched DetermaRx™, a treatment stratification test to identify early-stage lung cancer patients who are at high risk for cancer recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients who are more likely to respond to checkpoint inhibitor immunotherapies. The Company also plans to launch Therasure™-CNI MONITOR, a blood-based immune therapy monitoring test. Oncocyte’s pharmaceutical company services help pharmaceutical companies to develop new cancer treatments, many of which may be linked to Oncocyte’s diagnostic tests.
DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.
Oncocyte Forward-Looking Statements
Oncocyte cautions you that this press release contains forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to the commercial launch of DetermaRx, development of DetermaIO, pharmaceutical services, unexpected expenditures or assumed liabilities or other unanticipated difficulties resulting from acquisitions, licensing, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for Oncocyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on our financial and operational results, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to our supply chain, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize, and risks inherent in acquisitions such as failure to realize anticipated benefits, unexpected expenditures or assumed liabilities, unanticipated difficulties in conforming business practices including accounting policies, procedures and internal controls, greater than estimated allocations of resources to develop and commercialize technologies, or failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
LifeSci Advisors, LLC
Cait Williamson, Ph.D.
LifeSci Communications, LLC